This report presents a detailed case of an NSCLC patient with an acquired ROS1 L2086F resistance mutation who achieved substantial clinical benefit from cabozantinib, aiming to contribute valuable insights and evidence to this complex clinical scenario. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.